Evidence map›Paper›PMID 24642831›Full record

ArticleEuropean journal of human genetics : EJHG2014

A national perspective on prenatal testing for mitochondrial disease.

Victoria Nesbitt, Charlotte L Alston, Emma L Blakely, Carl Fratter, Catherine L Feeney, Joanna Poulton, Garry K Brown, Doug M Turnbull, Robert W Taylor, Robert McFarland

Open access · hybridAbstract read
In one paragraph

Article in European journal of human genetics : EJHG, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 1 pooled it
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 1 synthesis or guideline pooled it, 59 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. A clinical approach to diagnosis and management of mitochondrial myopathies.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2024
    Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. A retrospective study on the efficacy of prenatal diagnosis for pregnancies at risk of mitochondrial DNA disorders.Genetics in medicine : official journal of the American College of Medical Genetics · 2021
    Article
  12. Review
  13. Article
  14. Article
  15. Molecular basis of Leigh syndrome: a current look.Orphanet journal of rare diseases · 2020
    Review
  16. Review
  17. Article
  18. Diagnosis and Treatment of Mitochondrial Myopathies.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2018
    Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Victoria NesbittWellcome Trust Centre for Mitochondrial Research, The Medical School, Institute for Ageing and Health, Newcastle University, Newcastle-upon-Tyne, UK.
Charlotte L AlstonNHS Specialised Services for Rare Mitochondrial Disorders of Adults and Children UK, Oxford, UK.
Emma L BlakelyNHS Specialised Services for Rare Mitochondrial Disorders of Adults and Children UK, Oxford, UK.
Carl Fratter1] NHS Specialised Services for Rare Mitochondrial Disorders of Adults and Children UK, Oxford, UK [2] Oxford Medical Genetics Laboratories, Oxford University Hospitals NHS Trust, Oxford, UK.
Catherine L FeeneyNHS Specialised Services for Rare Mitochondrial Disorders of Adults and Children UK, Oxford, UK.
Joanna Poulton1] NHS Specialised Services for Rare Mitochondrial Disorders of Adults and Children UK, Oxford, UK [2] Nuffield Department of Obstetrics and Gynaecology, University of Oxford, John Radcliffe Hospital, Oxford, UK.
Garry K Brown1] NHS Specialised Services for Rare Mitochondrial Disorders of Adults and Children UK, Oxford, UK [2] Department of Biochemistry, University of Oxford, Oxford, UK.
Doug M Turnbull1] Wellcome Trust Centre for Mitochondrial Research, The Medical School, Institute for Ageing and Health, Newcastle University, Newcastle-upon-Tyne, UK [2] NHS Specialised Services for Rare Mitochondrial Disorders of Adults and Children UK, Oxford, UK.
Robert W Taylor1] Wellcome Trust Centre for Mitochondrial Research, The Medical School, Institute for Ageing and Health, Newcastle University, Newcastle-upon-Tyne, UK [2] NHS Specialised Services for Rare Mitochondrial Disorders of Adults and Children UK, Oxford, UK.
Robert McFarland1] Wellcome Trust Centre for Mitochondrial Research, The Medical School, Institute for Ageing and Health, Newcastle University, Newcastle-upon-Tyne, UK [2] NHS Specialised Services for Rare Mitochondrial Disorders of Adults and Children UK, Oxford, UK.
Wellcome Centre for Mitochondrial Research · GB

Funding

Department of Health NIHR-HCS-D12-03-04Medical Research Council G0601943Medical Research Council G0700718Medical Research Council G0800674Medical Research Council MR/K000608/1Wellcome Trust 096919Wellcome Trust 906919
6 · The paper itself

Abstract

Mitochondrial diseases affect >1 in 7500 live births and may be due to mutations in either mitochondrial DNA (mtDNA) or nuclear DNA (nDNA). Genetic counselling for families with mitochondrial diseases, especially those due to mtDNA mutations, provides unique and difficult challenges particularly in relation to disease transmission and prevention. We have experienced an increasing demand for prenatal diagnostic testing from families affected by mitochondrial disease since we first offered this service in 2007. We review the diagnostic records of the 62 prenatal samples (17 mtDNA and 45 nDNA) analysed since 2007, the reasons for testing, mutation investigated and the clinical outcome. Our findings indicate that prenatal testing for mitochondrial disease is reliable and informative for the nuclear and selected mtDNA mutations we have tested. Where available, the results of mtDNA heteroplasmy analyses from other family members are helpful in interpreting the prenatal mtDNA test result. This is particularly important when the mutation is rare or the mtDNA heteroplasmy is observed at intermediate levels. At least 11 cases of mitochondrial disease were prevented following prenatal testing, 3 of which were mtDNA disease. On the basis of our results, we believe that prenatal testing for mitochondrial disease is an important option for couples where appropriate genetic analyses and pre/post-test counselling can be provided.

Indexed as

Chorionic Villi SamplingDNA, MitochondrialGenetic CounselingGenetic TestingHumansMitochondriaMitochondrial DiseasesMutationPrenatal DiagnosisDNA, Mitochondrial

Identifiers

PMID24642831
PMCPMC4200441
OpenAlexW2163172128

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.